SG11202003800YA - Zika vaccines and immunogenic compositions, and methods of using the same - Google Patents

Zika vaccines and immunogenic compositions, and methods of using the same

Info

Publication number
SG11202003800YA
SG11202003800YA SG11202003800YA SG11202003800YA SG11202003800YA SG 11202003800Y A SG11202003800Y A SG 11202003800YA SG 11202003800Y A SG11202003800Y A SG 11202003800YA SG 11202003800Y A SG11202003800Y A SG 11202003800YA SG 11202003800Y A SG11202003800Y A SG 11202003800YA
Authority
SG
Singapore
Prior art keywords
methods
same
immunogenic compositions
zika vaccines
zika
Prior art date
Application number
SG11202003800YA
Inventor
Jill A Livengood
Holli Giebler
Whitney Baldwin
Hansi Dean
Claire Y H Kinney
Original Assignee
Takeda Vaccines Inc
The United States Of America As Represented By The Secretary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc, The United States Of America As Represented By The Secretary filed Critical Takeda Vaccines Inc
Publication of SG11202003800YA publication Critical patent/SG11202003800YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
SG11202003800YA 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same SG11202003800YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762581500P 2017-11-03 2017-11-03
US201762592995P 2017-11-30 2017-11-30
PCT/US2018/059219 WO2019090228A2 (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same

Publications (1)

Publication Number Publication Date
SG11202003800YA true SG11202003800YA (en) 2020-05-28

Family

ID=64427224

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11202003949TA SG11202003949TA (en) 2017-11-03 2018-11-05 Method for inactivating zika virus and for determining the completeness of inactivation
SG11202003796XA SG11202003796XA (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same
SG11202003800YA SG11202003800YA (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG11202003949TA SG11202003949TA (en) 2017-11-03 2018-11-05 Method for inactivating zika virus and for determining the completeness of inactivation
SG11202003796XA SG11202003796XA (en) 2017-11-03 2018-11-05 Zika vaccines and immunogenic compositions, and methods of using the same

Country Status (12)

Country Link
US (6) US11730802B2 (en)
EP (3) EP3703740A2 (en)
JP (4) JP7295124B2 (en)
KR (3) KR20200083571A (en)
CN (3) CN111511395B (en)
AU (6) AU2018359558C1 (en)
BR (3) BR112020008652A2 (en)
CA (3) CA3081581A1 (en)
MX (3) MX2020004542A (en)
MY (2) MY194449A (en)
SG (3) SG11202003949TA (en)
WO (3) WO2019090238A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111511395B (en) 2017-11-03 2024-10-15 武田疫苗股份有限公司 Methods for inactivating Zika virus and for determining completeness of inactivation
AU2018375173B2 (en) * 2017-11-30 2022-08-25 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
JP2022533550A (en) * 2019-05-08 2022-07-25 タケダ ワクチン，インコーポレイテッド Inactivated virus composition and Zika vaccine formulation
EP3892260A1 (en) * 2020-04-10 2021-10-13 Bayer Animal Health GmbH Immunostimulatory compositions based on liposomes with zwiterionic and cationic lipids
WO2021236845A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
EP4226155A1 (en) 2020-10-09 2023-08-16 Takeda Vaccines, Inc. Methods for determining complement-fixing antibodies
CN112980805B (en) * 2021-02-25 2022-11-08 中国科学院广州生物医药与健康研究院 Recombinant Zika virus attenuated strain and preparation method and application thereof
CN112941201B (en) * 2021-03-01 2022-03-08 武汉珈创生物技术股份有限公司 Mixed primer for multi-cell species identification and cross contamination detection and use method thereof
WO2023154043A1 (en) 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
KR102619184B1 (en) * 2022-12-27 2023-12-29 주식회사 그린백스 Vaccine composition comprising Zika virus inactivated by Epigallocatechin-3-gallate as an active ingredient

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
EP0382271B1 (en) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols as adjuvant in vaccine
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2649013B1 (en) 1989-07-03 1991-10-25 Seppic Sa VACCINES AND VECTORS OF FLUID ACTIVE INGREDIENTS CONTAINING METABOLIZABLE OIL
FR2649012B1 (en) 1989-07-03 1991-10-25 Seppic Sa INJECTABLE MULTIPHASIC EMULSIONS
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
ATE328890T1 (en) 1994-07-15 2006-06-15 Univ Iowa Res Found IMMUNOMODULATORY OLIGONUCLEOTIDES
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
DE19612966B4 (en) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK cells and methods of propagating influenza viruses
DE19612967A1 (en) 1996-04-01 1997-10-02 Behringwerke Ag Process for the propagation of influenza viruses in cell culture, and the influenza viruses obtainable by the process
JP4012252B2 (en) 1996-06-18 2007-11-21 アルザ コーポレイション Device for enhancing transdermal release or sampling of drugs
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
CN1133472C (en) 1996-12-20 2004-01-07 阿尔萨公司 Device and method for enhancing transdermal agent flux
AT405939B (en) * 1997-02-24 1999-12-27 Immuno Ag METHOD FOR INACTIVATING LIPID-ENVIRONED VIRUSES
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
US6309650B1 (en) 1997-08-28 2001-10-30 Cheil Jedang Corporation Attenuated Japanese encephalitis virus adapted to Vero cell and a Japanese encephalitis vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
DE69815692T2 (en) 1997-09-05 2004-04-29 Glaxosmithkline Biologicals S.A. OIL IN WATER EMULSIONS WITH SAPONINES
CA2305785A1 (en) 1997-10-07 1999-04-15 University Of Maryland Biotechnology Institute Method for introducing and expressing rna in animal cells
JP2001524533A (en) 1997-12-02 2001-12-04 パウダージェクト ヴァクシンズ，インコーポレイテッド Transdermal delivery of particulate vaccine compositions
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
DK1104306T3 (en) 1998-08-10 2006-05-22 Antigenics Inc Preparations of CpG and Saponin Adjuvants and Methods for Using Them
NZ511449A (en) 1998-12-02 2004-05-28 Univ Maryland Plasmid maintenance system for antigen delivery
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US7472098B2 (en) 2000-02-14 2008-12-30 Ubs Financial Services, Inc. System and method for execution of trades made pursuant to stock option and purchase plans
CA2430322A1 (en) 2000-11-22 2002-10-24 University Of Maryland, Baltimore Use of clya hemolysin for excretion of proteins
GB0326439D0 (en) 2003-11-13 2003-12-17 Imp College Innovations Ltd Methods
BRPI0419023A (en) 2004-08-27 2007-12-11 Panacea Biotec Ltd inactivated polio vaccine derived from the genus sabin of poliovirus
RS51665B (en) 2004-09-09 2011-10-31 Novartis Vaccines And Diagnostics Gmbh. Decreasing potential iatrogenic risks associated with influenza vaccines
EP1724338A1 (en) 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
US8865184B2 (en) 2006-09-01 2014-10-21 Bharat Biotech International Limited Vaccine for chikungunya virus infection
US8741311B2 (en) 2009-03-27 2014-06-03 Academia Sinica Methods and compositions for immunization against virus
CN101954076A (en) 2009-04-27 2011-01-26 免疫制剂美国公司 The immunotherapy of autoimmune hepatitis and prevention
US20140112953A1 (en) 2011-05-26 2014-04-24 Glaxo Smithkline Biologicals Sa Inactivated dengue virus vaccine
EP2720715B1 (en) 2011-06-17 2017-08-09 Bharat Biotech International Limited Vaccine composition comprising an inactivated chikungunya virus strain
DK2788023T3 (en) 2011-12-06 2016-12-19 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
ES2750366T3 (en) 2012-03-08 2020-03-25 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
CN104159603A (en) 2012-03-08 2014-11-19 诺华股份有限公司 Combination vaccines with tlr4 agonists
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
AU2014338520B2 (en) 2013-09-14 2019-12-05 Bharat Biotech International Limited A viral vaccine and methods of manufacture thereof
EP3194595A4 (en) 2014-09-17 2018-06-20 University of Iowa Research Foundation Viral rna segments as immunomodulatory agents and vaccine components
JP6755243B2 (en) 2014-10-07 2020-09-16 セラム インスティチュート オブ インディア プライベイト リミテッド Improved methods for enterovirus inactivation and adjuvant adsorption, and the resulting dose-reducing vaccine compositions.
MA40920A (en) 2014-11-07 2017-09-12 Takeda Vaccines Inc VACCINES OF THE HAND, FOOT AND MOUTH, AND METHODS OF MANUFACTURING AND USE THEREOF
US10086061B2 (en) 2015-03-11 2018-10-02 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
CN108472353A (en) 2015-06-22 2018-08-31 哈佛大学校长及研究员协会 Composition and method for adjusting virus infection
EA035921B1 (en) * 2015-07-16 2020-08-31 Бхарат Байотек Интернэшнл Лимитед Vaccine compositions for prophylaxis of arbovirus infections
US11007260B2 (en) 2015-07-21 2021-05-18 Modernatx, Inc. Infectious disease vaccines
WO2017056094A1 (en) 2015-09-30 2017-04-06 Ramot At Tel-Aviv University Ltd. Attenuated virus mutated at sites of evolutionarily conserved rna structure
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
SG11201805120YA (en) * 2015-12-23 2018-07-30 Valneva Austria Gmbh Zika virus vaccine
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
US11434259B2 (en) 2016-01-25 2022-09-06 Iogenetics, Llc Modified Zika virus NS1 protein with reduced cross-reactive immunogenicity
SG10201913630YA (en) * 2016-02-17 2020-03-30 Curevac Ag Zika virus vaccine
CN109152826B (en) 2016-02-25 2022-11-04 宾夕法尼亚大学理事会 Novel vaccine against Zika virus
US20170354729A1 (en) 2016-03-16 2017-12-14 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
CN105749268B (en) 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 Inactivated Zika virus vaccine
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
WO2017192856A1 (en) 2016-05-04 2017-11-09 University Of Miami Zika virus vector for treating zika virus infection
EP3454894B1 (en) 2016-05-10 2022-07-27 Najit Technologies, Inc. Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
EP3463445A1 (en) 2016-06-02 2019-04-10 GlaxoSmithKline Biologicals SA Zika viral antigen constructs
US10611801B2 (en) 2016-06-09 2020-04-07 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for preventing and treating Zika virus infection
GB201610162D0 (en) 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
CA3026807A1 (en) 2016-06-13 2017-12-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
WO2018009603A1 (en) 2016-07-08 2018-01-11 The United State of America, as represented by the Secretary, Department of Health and Human Service Chimeric west nile/zika viruses and methods of use
EP3481848B1 (en) 2016-07-08 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Genomic sequences encoding for an attenuated mutant zika virus
WO2018022786A1 (en) 2016-07-26 2018-02-01 Washington University Antibodies to zika virus and methods of use thereof
GB201613191D0 (en) 2016-07-29 2016-09-14 Univ Oxford Innovation Ltd Zika virus vaccine
BE1025121B1 (en) 2016-11-17 2018-11-05 Glaxosmithkline Biologicals Sa ANTIGENIC CONSTRUCTS OF ZIKA VIRUS
EP3558353A2 (en) 2016-12-23 2019-10-30 Expres2ion Biotechnologies ApS New flavivirus vaccine
CN108503697B (en) 2017-02-27 2023-03-31 中国科学院上海巴斯德研究所 Zika virus subunit vaccine expressed by drosophila cells
CN108503696B (en) 2017-02-27 2023-05-12 中国科学院上海巴斯德研究所 Zika virus subunit vaccine expressed by yeast cells
US11655471B2 (en) 2017-03-08 2023-05-23 University Of Georgia Research Foundation, Inc. Engineered cells with decreased gene expression resulting in increased viral production
WO2018187799A1 (en) 2017-04-07 2018-10-11 The Rockefeller University Compositions and methods related to human neutralizing antibodies to zika and dengue 1 virus
CN109081868B (en) 2017-06-14 2022-06-24 中国科学院上海巴斯德研究所 Monoclonal antibody targeting Zika virus envelope protein conserved epitope and application thereof
WO2018237039A1 (en) 2017-06-20 2018-12-27 Texas Tech University System Zika virus like particle (vlp) based vaccine and microneutralization assay
EP3417943B1 (en) 2017-06-21 2020-02-12 Eppendorf AG Centrifuge rotor with seal
CN107188935B (en) 2017-07-20 2018-10-02 北京健乃喜生物技术有限公司 A kind of zika virus NS1 antigenic mutants and its application
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
CN107537029B (en) 2017-09-14 2021-03-19 北京科兴生物制品有限公司 Zika virus and yellow fever virus combined inactivated vaccine
GB201716254D0 (en) 2017-10-05 2017-11-22 Univ Leuven Kath Live-attenuated flaviruses with heterologous antigens
CN111511395B (en) 2017-11-03 2024-10-15 武田疫苗股份有限公司 Methods for inactivating Zika virus and for determining completeness of inactivation
BR102017024030A2 (en) 2017-11-08 2019-06-04 Universidade Federal De São João Del Rei IMMUNOGENIC RECOMBINANT PROTEIN WITH ZIKA ANTIGENS FOR VACCINE VIRUS AND ITS USES
US20210054055A1 (en) 2017-11-21 2021-02-25 The University Of Vermont And State Agricultural College Highly specific zika neutralizing human antibodies
AU2018375173B2 (en) 2017-11-30 2022-08-25 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
CN108187036A (en) 2017-12-08 2018-06-22 北京科兴中维生物技术有限公司 A kind of zika virus combines inactivated vaccine with encephalitis B virus
CN108210921A (en) 2017-12-29 2018-06-29 广州恩宝生物医药科技有限公司 A kind of zika virus vaccine and preparation method thereof
EP3755818A1 (en) 2018-02-22 2020-12-30 Nano4 Global, Lda Method for detecting flaviviridae
EP3762021A4 (en) 2018-03-08 2022-01-26 Codagenix Inc. Attenuated flaviviruses
BR112020019719A2 (en) 2018-03-29 2021-01-26 Emergex Vaccines Holding Limited vaccine compositions
KR102075581B1 (en) 2018-04-27 2020-02-10 가톨릭대학교 산학협력단 Adjuvant comprising nucleic acid molecule inserted viral expression regulation sequence and phamraceutical composition having the adjuvant
WO2020017765A1 (en) 2018-07-18 2020-01-23 (주)진매트릭스 Zika virus variant and zika vaccine composition comprising same
US20220118077A1 (en) 2018-09-11 2022-04-21 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
EP3870208A4 (en) 2018-10-26 2022-10-26 New York Blood Center, Inc. Zika virus immunogenic compositions
JP7463366B2 (en) 2018-11-20 2024-04-08 タケダ ワクチン，インコーポレイテッド Novel anti-Zika virus antibodies and uses thereof
JP2022533550A (en) 2019-05-08 2022-07-25 タケダ ワクチン，インコーポレイテッド Inactivated virus composition and Zika vaccine formulation
US20230272405A1 (en) 2020-06-22 2023-08-31 University Of Connecticut Flavivirus signal peptides, vaccine constructs, and methods therefor

Also Published As

Publication number Publication date
WO2019090228A2 (en) 2019-05-09
EP3703741A1 (en) 2020-09-09
AU2018359556A1 (en) 2020-05-28
BR112020008665A2 (en) 2020-11-10
WO2019090233A2 (en) 2019-05-09
MX2020004543A (en) 2020-09-18
JP2021502350A (en) 2021-01-28
JP7295124B2 (en) 2023-06-20
AU2018359556B2 (en) 2021-12-02
AU2022203422A1 (en) 2022-06-09
US11648304B2 (en) 2023-05-16
AU2022203422B2 (en) 2023-10-05
CA3081581A1 (en) 2019-05-09
WO2019090228A3 (en) 2019-06-20
AU2022201109A1 (en) 2022-03-10
CN111511395A (en) 2020-08-07
CN111615397B (en) 2024-09-13
US20210177959A1 (en) 2021-06-17
MY194449A (en) 2022-11-30
CN111511395B (en) 2024-10-15
AU2022201109B9 (en) 2022-05-12
WO2019090238A1 (en) 2019-05-09
MY193736A (en) 2022-10-27
AU2022209239B2 (en) 2023-10-05
AU2018359660B2 (en) 2022-02-24
JP2021502075A (en) 2021-01-28
SG11202003796XA (en) 2020-05-28
US11964008B2 (en) 2024-04-23
US20200360505A1 (en) 2020-11-19
EP3703739A2 (en) 2020-09-09
AU2018359558A1 (en) 2020-05-28
MX2020004542A (en) 2020-09-18
AU2022209239A1 (en) 2022-08-18
KR20200117981A (en) 2020-10-14
KR20200085302A (en) 2020-07-14
BR112020008652A2 (en) 2020-11-10
EP3703740A2 (en) 2020-09-09
CA3081586A1 (en) 2019-05-09
JP7443232B2 (en) 2024-03-05
CN111615397A (en) 2020-09-01
AU2018359558B2 (en) 2021-12-02
US11478541B2 (en) 2022-10-25
AU2018359660A1 (en) 2020-05-28
CN111526885A (en) 2020-08-11
US20210177958A1 (en) 2021-06-17
US20240325518A1 (en) 2024-10-03
US11730802B2 (en) 2023-08-22
JP2023175761A (en) 2023-12-12
JP2021505648A (en) 2021-02-18
SG11202003949TA (en) 2020-05-28
US20230145065A1 (en) 2023-05-11
AU2018359558C1 (en) 2022-09-22
MX2020004367A (en) 2020-10-19
AU2022201109B2 (en) 2022-04-28
KR20200083571A (en) 2020-07-08
BR112020008693A2 (en) 2020-10-13
WO2019090233A3 (en) 2019-06-13
US12109260B2 (en) 2024-10-08
US20230414743A1 (en) 2023-12-28
CA3081578A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
SG11202003796XA (en) Zika vaccines and immunogenic compositions, and methods of using the same
HUS2200035I1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
HK1250136A1 (en) Vaccine compositions having improved stability and immunogenicity
ZA202000889B (en) An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
IL268168A (en) Immunogenic compositions for use in pneumococcal vaccines
SG11202004863QA (en) Zika vaccines and immunogenic compositions, and methods of using the same
IL269590A (en) Methods and compositions for reduction of immunogenicity
IL251120A0 (en) Immunogenic/therapeutic glycoconjugate compositions and uses thereof
GB201711635D0 (en) Immunogenic composition
SG11201803581VA (en) Chimeric RSV, Immunogenic Compositions, and Methods of Use
GB201711637D0 (en) Immunogenic composition
GB201721582D0 (en) S aureus antigens and immunogenic compositions
EP3307311A4 (en) Multivalent enterovirus vaccine compositions and uses related thereto
IL271603A (en) Immunogenic compositions
IL258700A (en) Adjuvant and vaccine composition containing the same
GB201800417D0 (en) Immunogenic agent and associated compositions, uses and methods
GB201911959D0 (en) Immunogenic compositions and uses therefor
SG11202004167XA (en) Immunogenic compositions and uses therefor
AU2017904540A0 (en) Immunogenic compositions and uses therefor
AU2014902031A0 (en) Immunogenic vaccines and uses thereof